Not recruitingISRCTN03554974

Efficacy and safety of agomelatine for 12 weeks in non-depressed out-patients with Generalised Anxiety Disorder

Research studyAges 18+Multiple countries

The study in practice

Understand this study

This study is for people with anxiety. Listed age limits: from 18 years. Other eligibility criteria apply.

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Study start dateNot clearly listed

Recruitment status: Not recruiting
Enrollment listed in the registry: Not clearly listed
Sponsor: Institut de Recherches Internationales Servier (France)
Sponsor type: Research institute
Study type: Other
Intervention type: Other / unclear
Study phase: Not clearly listed
Locations: Argentina, Czechia, Finland, ...
Age range: Over 18 Years
Official registry ID: ISRCTN03554974
Official title: Show the full official title
Efficacy and safety of agomelatine for 12 weeks in non-depressed out-patients with Generalised Anxiety Disorder

The HopeStage team will email you.

Not recruiting

Argentina · Czechia · Finland

4 more locations

A listed location does not confirm current availability.

FAQ

Who is behind this study?

The study sponsor is Institut de Recherches Internationales Servier (France), a research institute.

Who can participate?

This study is for people with anxiety. Listed age limits: from 18 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as not recruiting.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.